parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in podocytes	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 9531

receipt 9539: FMN2 in dopamine neurons, braak

power: full sample +0.35 (p 0.153, n 18), 95% CI -0.14 to +0.70. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.43 (p 0.074, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.43 (p 0.074, n 18). could be the mix.
skeptic: leave-one-out range +0.27 to +0.52, sign flips 0; without severely affected donors +0.35 (p 0.153, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FMN2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 9538: FMN2 in astrocytes, braak

power: full sample +0.01 (p 0.969, n 18), 95% CI -0.46 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.03 (p 0.901, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: -0.00 (p 0.997, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.16, sign flips 7; without severely affected donors +0.01 (p 0.969, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for FMN2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts